1 Min Read
Sept 27 (Reuters) - Revive Therapeutics Ltd:
* Revive Therapeutics applies to FDA for orphan drug designation for treatment of autoimmune hepatitis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.